The primary objectives of this study are to evaluate the efficacy, safety and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in treatment-naive and treatment-experienced participants with chronic genotype 1 Hepatitis C Virus (HCV) infection.